Retacrit Shortage Update: What Patients Need to Know in 2026

If you rely on Retacrit (epoetin alfa-epbx) to manage anemia — whether from chronic kidney disease, cancer chemotherapy, or HIV treatment — you deserve a clear, up-to-date picture of the supply situation. Here's what we know about the Retacrit shortage history and current status heading into 2026.

Current Retacrit Shortage Status (2026)

As of mid-2025, ASHP (the American Society of Health-System Pharmacists) confirmed that Pfizer has Retacrit available. There is no active nationwide shortage designation for Retacrit heading into 2026. However, this does not mean every pharmacy or specialty pharmacy will have every strength in stock. Localized shortages of specific vial strengths (e.g., 2,000 Units/mL or 10,000 Units/mL) can still occur at the regional or facility level.

Additionally, Epogen (the reference product by Amgen) has had documented shortages of certain strengths listed on the ASHP shortage database as recently as 2025, which can increase demand for Retacrit as a substitute — potentially straining local supply even when Retacrit is broadly available.

Retacrit Shortage History: A Timeline

Retacrit's supply has been disrupted multiple times since its U.S. launch in 2018:

• May 2022: Pfizer notified payers of a supply disruption beginning in late May 2022. The company targeted a return to supply by early Q4 2022. Patients were advised to switch to Epogen or Procrit during the disruption.
• September 2023: A second supply disruption emerged. At least one major insurer (EmblemHealth) temporarily suspended Retacrit as the preferred ESA under the medical benefit, reverting to Epogen/Procrit during this period.
• 2024–2025: Retacrit availability improved. ASHP's shortage database (updated June 27, 2025) listed Pfizer's Retacrit as available. No new national shortage was declared.
• 2026: No active national shortage, but localized supply gaps remain possible given the specialty nature of the drug and ongoing ESA category strain.

Why Does Retacrit Keep Having Shortages?

The root causes of Retacrit supply disruptions are similar to those seen across the specialty biologic drug category:

1. Manufacturing complexity. Retacrit is a biologic made using living Chinese hamster ovary (CHO) cell cultures. The manufacturing process is far more complex and sensitive than producing small-molecule generic drugs. A single quality deviation or facility issue can halt production for weeks.
2. Facility inspections and compliance. FDA inspections of sterile injectable manufacturing facilities have been a recurring challenge across the pharmaceutical industry. Any FDA warning letter or manufacturing concern can delay production and distribution.
3. Concentrated manufacturing base. With only one approved manufacturer for Retacrit (Pfizer/Hospira), any disruption at the single production facility directly affects the entire U.S. supply — there is no backup manufacturer to absorb the gap.
4. Cold chain distribution challenges. As a refrigerated biologic, Retacrit cannot be stored at room temperature. Cold chain logistics add complexity to distribution, limiting the number of stocking points.

How Does a Retacrit Shortage Affect Patients?

For patients who depend on Retacrit, supply interruptions can have real consequences:

• Missed doses allow hemoglobin to decline, potentially requiring hospitalization or blood transfusions
• Switching to Epogen or Procrit requires prescriber authorization and insurer approval — adding delays of days to weeks
• Patients switching to brand-name alternatives may face higher out-of-pocket costs, especially if Retacrit was their insurer's preferred product
• Dialysis patients have less flexibility, as their ESA doses are often administered on a strict schedule during hemodialysis sessions

What Should You Do If You're Having Trouble Finding Retacrit?

Here are your key action steps:

1. Contact your prescriber's office immediately — don't wait until you run out.
2. Use medfinder to check which specialty pharmacies in your area currently have your Retacrit strength in stock.
3. Ask your doctor about temporarily switching to Epogen, Procrit, or Aranesp while supply is restored.
4. Contact Pfizer Oncology Together at 1-877-744-5675 for patient support resources.
5. Check the ASHP Drug Shortage Database (ashp.org) for the most current official shortage status.

The Bottom Line

Retacrit does not currently have an active national shortage designation heading into 2026, but its supply history — with major disruptions in 2022 and 2023 — means patients should always plan ahead, maintain open communication with their prescriber, and know their alternatives. Read our guide on how to find Retacrit in stock near you for practical next steps.